
John C. Byrd, MD - Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety Management
01/20/22 • 85 min
Previous Episode

John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci - Achieving Innovation in CLL Care: Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management
Go online to PeerView.com/FZU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Test yourself and take a tour with a “Tumor Board” on modern care for chronic lymphocytic leukemia (CLL). This activity, developed in collaboration with the CLL Society, features a panel of leading CLL experts blending serial, case-based discussion with mini seminars designed to illustrate how the personalized use of targeted therapeutics—including BTK and BCL-2 inhibitors—can improve care across the clinical spectrum of CLL. Upon completion of this activity, participants should be better able to: Cite current efficacy and safety data surrounding novel therapeutic classes in CLL, including evidence with BTK, PI3K, and BCL-2 inhibitors and novel combinations, Apply evidence on current prognostic factors, genetic/molecular findings, and patient- or disease-related features when making treatment decisions in CLL, Develop an optimal treatment plan with targeted agents, including fixed-duration or continuous therapy, or appropriate combinatorial or sequential options for patients presenting with treatment-naïve or relapsed/refractory CLL, Manage unique safety considerations associated with the use of targeted agents, novel antibodies, or cellular therapies in the CLL setting.
Next Episode

Stephen R. Broderick, MD, MPHS/Heather A. Wakelee, MD - Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multidisciplinary Alliances to Improve Outcomes in Early-Stage Disease
Go online to PeerView.com/HSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) are swiftly transitioning from the metastatic to early-stage settings and are expected to transform the multimodal management of patients with resectable stage I-III NSCLC. Remarkable data have emerged from several trials assessing ICIs and rational combinations as neoadjuvant and/or adjuvant therapies, but many questions remain and misperceptions persist. What are the pros/cons of neoadjuvant versus adjuvant immunotherapy, and how should the best approach be determined for each patient? What is the optimal duration of therapy, and how should responses be assessed? What adverse events should be anticipated, and are perioperative complications higher? This PeerView MasterClass, based on a recent live web broadcast, addresses these and many other essential topics. Watch this engaging discussion about new, practice-changing evidence, debates about implications and applicability to practice, and demonstrations of how to achieve better surgeon–oncologist partnerships to facilitate appropriate incorporation of ICIs into multimodal treatment plans for patients with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Describe the mechanistic aspects of immune checkpoint inhibition, rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer, and key clinical trials evaluating immunotherapy in these settings, Assess the real evidence and misconceptions related to the safety and adverse effects of checkpoint inhibitors when used in the treatment of patients with locally advanced and early-stage lung cancer as well as potential implications for surgical outcomes in these patients, Apply the latest evidence and guidelines for integrating immunotherapy into multimodal treatment plans in locally advanced and earlier stages of NSCLC, Collaborate with the multidisciplinary team to develop evidence-based, individualized treatment approaches for patients with stage III or earlier lung cancer in the context of clinical practice or clinical trials.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/peerview-oncology-and-hematology-cmecnecpe-video-podcast-25425/john-c-byrd-md-customizing-care-in-cll-with-btk-inhibitors-evidence-an-19021802"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to john c. byrd, md - customizing care in cll with btk inhibitors: evidence and applications for therapy selection, sequencing, and safety management on goodpods" style="width: 225px" /> </a>
Copy